Description
This research blend combines three growth hormone–axis peptides in a single lyophilized vial: tesamorelin, CJC-1295 without DAC (Mod GRF 1-29), and ipamorelin. The formulation pairs two structurally distinct GHRH analogs with a selective growth hormone secretagogue receptor (GHS-R) agonist, allowing concurrent investigation of GHRH and ghrelin/GHS pathway activation. Tesamorelin is a stabilized 44-amino-acid GHRH analog with a trans-3-hexenoic acid modification at the N-terminus and an extended plasma half-life. CJC-1295 (no DAC) is a 29-amino-acid modified GRF(1-29) sequence with substitutions designed to resist DPP-IV cleavage, offering a shorter pulsatile profile. Ipamorelin is a selective pentapeptide GHS-R agonist studied for its specificity over cortisol, prolactin, ACTH, and aldosterone pathways.
Benefits (Research Focus)
• Studied for combined GHRH receptor and GHS-R pathway activation
• Investigated for pulsatile growth hormone release patterns in research models
• Explored for downstream IGF-1 signaling and somatotropic axis endpoints
• Examined for differential effects on visceral adipose tissue in lipodystrophy models
• Researched for receptor selectivity and minimal off-target hormone activity
What Researchers Look At
• Plasma GH and IGF-1 dynamics following administration
• Pulsatile vs sustained GH release across paired GHRH and GHS-R stimulation
• Visceral adipose tissue and lipid metabolism endpoints
• Cortisol, prolactin, and ACTH response (selectivity markers)
• DPP-IV resistance and peptide pharmacokinetic profiles
Quick Specs
• Form: Lyophilized white powder
• Tesamorelin: 6 mg per vial
• CJC-1295 (no DAC): 3 mg per vial
• Ipamorelin: 3 mg per vial
• Total Peptide Content: 12 mg per vial
• Quantity: 1 vial
• Purity: ≥99% by HPLC (per component)
• Appearance: White to off-white lyophilizate
• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)
• Storage: Protect from light
Identity Basics
• Compound 1: Tesamorelin
• Class: Stabilized GHRH(1-44) analog with N-terminal trans-3-hexenoic acid modification
• Chemical Formula: C₂₂₁H₃₆₆N₇₂O₆₇S
• Molecular Weight: 5135.86 g/mol
• CAS: 218949-48-5
• Compound 2: CJC-1295 without DAC (Mod GRF 1-29)
• Class: Modified GHRH(1-29) analog with D-Ala², Gln⁸, Ala¹⁵, Leu²⁷ substitutions
• Chemical Formula: C₁₅₂H₂₅₂N₄₄O₄₂
• Molecular Weight: 3367.95 g/mol
• CAS: 863288-34-0
• Compound 3: Ipamorelin
• Class: Selective ghrelin / GHS-R agonist (pentapeptide)
• Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂
• Chemical Formula: C₃₈H₄₉N₉O₅
• Molecular Weight: 711.85 g/mol
• CAS: 170851-70-4
⚠️ Disclaimer
- This product is intended for laboratory research use only.
- Not for human or veterinary use.
- Not approved for diagnostic, therapeutic, or medical applications.
- Handle using appropriate laboratory safety procedures and personal protective equipment.
